Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing